scholarly journals Evaluation of the antiulcerogenic activity of hydromethanol extracts of Solanum incanum L. (Solanaceae) leaves and roots in mice; single and repeated dose study

2021 ◽  
pp. 100119
Author(s):  
Yaschilal Muche Belayneh ◽  
Gedefaw Getnet Amare ◽  
Birhanu Geta Meharie ◽  
Zemene Demelash Kifle
Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 751-P
Author(s):  
HARUNOBU NISHIZAKI ◽  
OSAMU MATSUOKA ◽  
MEGURU ACHIRA ◽  
TOMOYA KAGAWA ◽  
MASANORI WATANABE ◽  
...  

2018 ◽  
Vol 295 ◽  
pp. S217
Author(s):  
J. Kanno ◽  
S. Kitajima ◽  
R. Ono ◽  
K. Aisaki
Keyword(s):  

2011 ◽  
pp. 190
Author(s):  
Melva Louisa ◽  
Vivian Soetikno ◽  
Nafrialdi Nafrialdi ◽  
Rianto Setiabudy ◽  
Frans D. Suyatna

2012 ◽  
Vol 31 (1) ◽  
pp. 58-69 ◽  
Author(s):  
Padmaja Yerramilli-Rao ◽  
M. Flint Beal ◽  
Dai Watanabe ◽  
Karl Kieburtz ◽  
Elisabeth A. de Blieck ◽  
...  

To support phase III testing of coenzyme Q10 (CoQ10) in humans, we conducted pharmacokinetic and toxicology studies in beagle dogs. Following single gavage administration of CoQ10 at 600, 1200, 1800, or 2400 mg/kg per d no obvious dose response was observed in maximum concentration ( Cmax) or area under the curve (AUC) versus time curve at the 3 highest dosages. In a repeated-dose study of CoQ10 at 600, 1200, 1800, or 2400 mg/kg per d for 4 weeks, CoQ10 reached steady state in plasma by 2 weeks at all dosages. Both Cmax and AUC increased with increasing dosage of CoQ10. The highest plasma levels were recorded at 1800 mg/kg per d. In a 39-week chronic toxicity study of CoQ10 at 1200 and 1800 mg/kg per d or placebo, CoQ10 reached steady state in plasma by 13 weeks. Behaviors, blood chemistries, and detailed histopathology were normal. No deaths occurred. These results support the use of a 2400 mg/d dosage of CoQ10 in human clinical trials.


2017 ◽  
Vol 90 ◽  
pp. 850-862 ◽  
Author(s):  
Yanet C. Ocampo ◽  
Daneiva C. Caro ◽  
David E. Rivera ◽  
Luis A. Franco

PROTEOMICS ◽  
2007 ◽  
Vol 7 (5) ◽  
pp. 781-795 ◽  
Author(s):  
Hidenori Yamanaka ◽  
Yoshikuni Yakabe ◽  
Koichi Saito ◽  
Masaru Sekijima ◽  
Tomoyuki Shirai

2014 ◽  
Vol 36 (4) ◽  
pp. 191-198 ◽  
Author(s):  
Takafumi Kimoto ◽  
Satsuki Chikura ◽  
Kumiko Suzuki-Okada ◽  
Xiaomei Kobayashi ◽  
Yasuhiro Itano ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
B. Chitra ◽  
R. S. Ramaswamy ◽  
V. Suba

Pũrṇa Cantirotaya Centũram (PCC), a herbometallic formulation of Siddha medicine, consists of mercury, sulphur, and gold, processed with red cotton flower and plantain stem pith juices. To evaluate its safety, acute and 28-day repeated oral toxicity studies were performed following OECD test guidelines 423 and 407, respectively. In acute study, PCC was administered orally at 5, 50, 300, and 2000 mg/kg body weight. Animals were observed for toxic signs for 14 days. Gross pathology was performed at the end of the study. In repeated dose toxicity study, PCC was administered at 2.5, 25, and 50 mg/kg body weight daily for 28 days. Satellite groups (control and high dose) were also maintained to determine the delayed onset toxicity of PCC. In acute toxicity study, no treatment related death or toxic signs were observed. It revealed that the LD50 cut-off value of PCC is between 2000 and 5000 mg/kg body weight. The repeated dose study did not show evidence of any treatment related changes in all observations up to the high dose level, when compared with the control. Histopathological examination revealed no abnormalities except mild hyperplasia of stomach in high dose group. This study provides scientific validation for the safety of PCC.


2005 ◽  
Vol 19 (4) ◽  
pp. 468-474 ◽  
Author(s):  
Gurkan Turker ◽  
Suna Goren ◽  
Sami Bayram ◽  
Sukran Sahin ◽  
Gulsen Korfali

Sign in / Sign up

Export Citation Format

Share Document